546 related articles for article (PubMed ID: 30341513)
1. Predictive Value of BRAF
Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.
Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H
Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400
[TBL] [Abstract][Full Text] [Related]
3. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
[TBL] [Abstract][Full Text] [Related]
4. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
5. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Kim TH; Park YJ; Lim JA; Ahn HY; Lee EK; Lee YJ; Kim KW; Hahn SK; Youn YK; Kim KH; Cho BY; Park DJ
Cancer; 2012 Apr; 118(7):1764-73. PubMed ID: 21882184
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.
Tao Y; Wang F; Shen X; Zhu G; Liu R; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Zhao S; Wang Y; Xing M
J Clin Endocrinol Metab; 2021 Oct; 106(11):3228-3238. PubMed ID: 34273152
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation.
Han Y; Hou L; Zhao B; Gao L; Li S
Front Endocrinol (Lausanne); 2022; 13():884428. PubMed ID: 35784548
[TBL] [Abstract][Full Text] [Related]
9. Integrating BRAF
Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
[TBL] [Abstract][Full Text] [Related]
10. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
11. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
[TBL] [Abstract][Full Text] [Related]
14. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
[TBL] [Abstract][Full Text] [Related]
15. Integrating US-guided FNAB, BRAF
Ma N; Tian HY; Yu ZY; Zhu X; Zhao DW
Eur Arch Otorhinolaryngol; 2023 Dec; 280(12):5565-5574. PubMed ID: 37540271
[TBL] [Abstract][Full Text] [Related]
16. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
17. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
18. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
19. Predicting factors of central lymph node metastasis and BRAF
Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
[TBL] [Abstract][Full Text] [Related]
20. Cytomorphological factors and BRAF mutation predicting risk of lymph node metastasis in preoperative liquid-based fine needle aspirations of papillary thyroid carcinoma.
Chung SY; Lee JS; Lee H; Park SH; Kim SJ; Ryu HS
Acta Cytol; 2013; 57(3):252-8. PubMed ID: 23636013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]